The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma

[1]  C. Horak,et al.  Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.

[2]  Antoni Ribas,et al.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.

[3]  Bernd Hauck,et al.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.

[4]  J. Wolchok,et al.  Patient Responses to Ipilimumab, a Novel Immunopotentiator for Metastatic Melanoma: How Different are these From Conventional Treatment Responses? , 2012, American journal of clinical oncology.

[5]  J. Kirkwood,et al.  IFN-α in the Treatment of Melanoma , 2012, The Journal of Immunology.

[6]  Donald L Weaver,et al.  Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  A. Hauschild,et al.  Management of immune-related adverse events and kinetics of response with ipilimumab. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[9]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[10]  W. Urba,et al.  Phase 1 Study of Stereotactic Body Radiotherapy and Interleukin-2—Tumor and Immunological Responses , 2012, Science Translational Medicine.

[11]  R. Elashoff,et al.  Metastasectomy for Distant Metastatic Melanoma: Analysis of Data from the First Multicenter Selective Lymphadenectomy Trial (MSLT-I) , 2012, Annals of Surgical Oncology.

[12]  W. Hwu,et al.  Ipilimumab in the treatment of melanoma , 2012, Expert opinion on biological therapy.

[13]  J. Wolchok,et al.  Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. , 2012, The Lancet. Oncology.

[14]  C. Drake,et al.  Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. , 2012, Current opinion in immunology.

[15]  Jedd D. Wolchok,et al.  Immunologic correlates of the abscopal effect in a patient with melanoma. , 2012, The New England journal of medicine.

[16]  S. Rosenberg,et al.  CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma , 2012, Clinical Cancer Research.

[17]  D. Schadendorf,et al.  Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. , 2012, European journal of cancer.

[18]  R. Scolyer,et al.  Surgical Management of Melanoma Lung Metastasis: An Analysis of Survival Outcomes in 292 Consecutive Patients , 2012, Annals of Surgical Oncology.

[19]  D. Morton,et al.  Does metastasectomy improve survival in patients with stage IV melanoma? a cancer registry analysis of outcomes , 2011, Journal of surgical oncology.

[20]  Axel Hoos,et al.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.

[21]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[22]  H. Dienemann,et al.  Survival after Pulmonary Metastasectomy in Patients with Malignant Melanoma , 2011, The Thoracic and cardiovascular surgeon.

[23]  S. Aamdal,et al.  Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial. , 2011, The Lancet. Oncology.

[24]  R. Go,et al.  Level of scientific evidence underlying recommendations arising from the National Comprehensive Cancer Network clinical practice guidelines. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  A. Hauschild,et al.  The Oncologist® Academia–Pharma Intersect: Melanoma , 2022 .

[26]  J. Kirkwood,et al.  Prognostic significance of autoimmunity during treatment of melanoma with interferon , 2006, Seminars in Immunopathology.

[27]  S. Greenfield,et al.  Clinical practice guidelines we can trust , 2011 .

[28]  A. Hauschild,et al.  Dose-Dependent Development of Depressive Symptoms During Adjuvant Interferon-α Treatment of Patients With Malignant Melanoma , 2010 .

[29]  Sylvia Janetzki,et al.  Improved Endpoints for Cancer Immunotherapy Trials , 2010, Journal of the National Cancer Institute.

[30]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[31]  H. Kaufman,et al.  OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. , 2010, Future oncology.

[32]  W. Burns,et al.  A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas. , 2010, Cancer research.

[33]  P. Gimotty,et al.  Predicting Survival Outcome of Localized Melanoma: An Electronic Prediction Tool Based on the AJCC Melanoma Database , 2010, Annals of Surgical Oncology.

[34]  M. Weichenthal,et al.  Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  D. Schadendorf,et al.  Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. , 2010, The Lancet. Oncology.

[36]  J. Stockman.  Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial , 2010 .

[37]  R. Berg,et al.  A Systematic Review and Meta-analysis , 2010 .

[38]  A. Hauschild,et al.  Dose-dependent development of depressive symptoms during adjuvant interferon-{alpha} treatment of patients with malignant melanoma. , 2010, Psychosomatics.

[39]  S. Mocellin,et al.  Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. , 2010, Journal of the National Cancer Institute.

[40]  Jeffrey E Gershenwald,et al.  Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Axel Hoos,et al.  Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.

[42]  M. Weichenthal,et al.  Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  D. Schadendorf,et al.  Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  K Ann McKibbon,et al.  Current status and future prospects. , 2008, Health information and libraries journal.

[45]  A. Hauschild,et al.  Practical guidelines for the management of interferon‐α‐2b side effects in patients receiving adjuvant treatment for melanoma , 2008, Cancer.

[46]  F. Schmidt.  Meta-Analysis , 2008 .

[47]  J. Wolchok,et al.  The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases. , 2008, Cancer immunity.

[48]  S. Sleijfer,et al.  Interferon-α Influences Tryptophan Metabolism without Inducing Psychiatric Side Effects , 2007, Neuropsychobiology.

[49]  J. Weber.  Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. , 2007, The oncologist.

[50]  S. Sleijfer,et al.  Interferon-alpha influences tryptophan metabolism without inducing psychiatric side effects. , 2007, Neuropsychobiology.

[51]  M. Atkins,et al.  Autoimmunity and immunotherapy for cancer. , 2006, The New England journal of medicine.

[52]  C. Slingluff,et al.  Autoimmune Toxicities Associated with the Administration of Antitumor Vaccines and Low-Dose Interleukin-2 , 2005, Journal of immunotherapy.

[53]  M. Schwarz,et al.  Correlation between sICAM-1 and depressive symptoms during adjuvant treatment of melanoma with interferon-α , 2004, Brain, Behavior, and Immunity.

[54]  J. Manola,et al.  A Pooled Analysis of Eastern Cooperative Oncology Group and Intergroup Trials of Adjuvant High-Dose Interferon for Melanoma , 2004, Clinical Cancer Research.

[55]  C. Mélot,et al.  Interferon Alpha as Adjuvant Postsurgical Treatment of Melanoma: A Meta-Analysis , 2004, Dermatology.

[56]  A. Hauschild,et al.  Suppressed thyroid-stimulating hormone secretion in patients treated with interleukin-2 and interferon-α2b for metastatic melanoma , 1994, The clinical investigator.

[57]  M. Gore,et al.  Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  M. Weichenthal,et al.  Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  A. Eggermont,et al.  Serum amino acids, biopterin and neopterin during long-term immunotherapy with interferon-alpha in high-risk melanoma patients , 2003, Psychiatry Research.

[60]  C. Nemeroff,et al.  Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. , 2003, The American journal of psychiatry.

[61]  S. Chauvie,et al.  Feasibility of Intensity-Modulated Radiation Therapy in the Treatment of Advanced Cervical Chordoma , 2003, Tumori.

[62]  D. Amadori,et al.  [Adjuvant adoptive immunotherapy in patients with stage III and resected stage IV melanoma: a pilot study]. , 2003, Tumori.

[63]  J. Matheson,et al.  Induction of Myasthenia Gravis, Myositis, and Insulin-Dependent Diabetes Mellitus by High-Dose Interleukin-2 in a Patient With Renal Cell Cancer , 2002, Journal of immunotherapy.

[64]  A. Abbruzzese,et al.  Low-dose recombinant IL-2 induces psychological changes: monitoring by Minnesota Multiphasic Personality Inventory (MMPI). , 2002, Anticancer research.

[65]  D. Schwartzentruber.  Guidelines for the Safe Administration of High-Dose Interleukin-2 , 2001, Journal of immunotherapy.

[66]  V. Sondak,et al.  High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  A K Manatunga,et al.  Paroxetine for the prevention of depression induced by high-dose interferon alfa. , 2001, The New England journal of medicine.

[68]  V. Sondak,et al.  High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  M. Atkins,et al.  High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. , 2000, The cancer journal from Scientific American.

[70]  H. Gutman,et al.  Toxicity of adjuvant high-dose interferon-alpha-2b in patients with cutaneous melanoma at high risk of recurrence. , 1999, Oncology reports.

[71]  R. Fisher,et al.  High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  S. Pyrhönen,et al.  Regimens with or without interferon-alpha as treatment for metastatic melanoma and renal cell carcinoma: an overview of randomized trials. , 1999, Journal of immunotherapy.

[73]  C. Chastang,et al.  Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1·5 mm without clinically detectable node metastases , 1998, The Lancet.

[74]  M. Atkins,et al.  A two-part phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptor. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[75]  S. Rosenberg,et al.  Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy. , 1998, The cancer journal from Scientific American.

[76]  C. Chastang,et al.  Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. , 1998, Lancet.

[77]  J. Kirkwood,et al.  Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  M. Atkins,et al.  Phase I trial of interleukin 2 in combination with the soluble tumor necrosis factor receptor p75 IgG chimera. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[79]  B. Dréno,et al.  Long-term interferon-alpha therapy induces autoantibodies against epidermis. , 1996, Dermatology.

[80]  P. Dietrich,et al.  Low‐dose IL‐2 treatment: Activation of discrete T‐ and NK‐cell sub‐populations in vivo , 1995, International journal of cancer.

[81]  S. Rosenberg,et al.  Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. , 1994, JAMA.

[82]  A. C. Dubbelman,et al.  Phase II study of intermittent continuous infusion of low-dose recombinant interleukin-2 in advanced melanoma and renal cell cancer. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[83]  W. Fridman,et al.  [Treatment of metastatic malignant melanoma with interleukin-2]. , 1992, Bulletin du cancer.

[84]  R. Stahel,et al.  Clinical and immune modulatory effects of alternative weekly interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma and melanoma. , 1991, British Journal of Cancer.

[85]  D. Longo,et al.  Randomized trial of recombinant alpha 2b-interferon with or without indomethacin in patients with metastatic malignant melanoma. , 1989, Cancer research.

[86]  Carl Wood,et al.  Current Status and Future Prospects , 1984 .

[87]  K. Digre,et al.  Expert Opinion , 1920, The Hospital.